Merck closed the second quarter looking like two companies stitched together. The operating business printed another clean beat, with second-quarter revenue of $16.6 billion rising 5% year over year. The accounting business, however, told a far uglier story. Merck took a $5.7 billion IPR&D charge in the quarter for the May acquisition of Terns, layered on top of the $9.0 billion Cidara charge booked in the first quarter. Those two together flipped the quarter to a GAAP net loss of roughly $(1.3) billion. Strip out those one-time deal charges and Merck's underlying earnings power remains intact, but the headline result is the kind of print that gets discounted mechanically by passive flows until non-GAAP earnings stabilize.
The defining event of the quarter is not the loss itself but the strategy behind it. With Keytruda approaching its 2028 U.S. loss-of-exclusivity cliff, management has chosen to convert shareholder cash into a pipeline of wholly-owned oncology assets through deals that accountants treat as expenses because the targets are clinical-stage companies with no marketed products. Merck shares traded near $151.64 at the time of this report. The fifty-two-week range runs from $77.58 to $156.92. Market capitalization sits at roughly $374 billion and the dividend yield is near 2.3%. The market has effectively valued the equity just below the fifty-two-week high. That positioning suggests investors are giving Merck credit for buying the pipeline rather than punishing it for the GAAP loss. Forward earnings power, excluding the IPR&D charges, ran near $2.13 per share in the prior-year quarter. Consensus expects a similar non-GAAP base going forward.
The strongest evidence supporting the bull case is that the underlying growth engines continue to compound. Keytruda and Keytruda Qlex combined revenue rose 8% in the first half to $16.4 billion. Welireg grew 67% in the quarter on the renal-cell approval combination with Keytruda. Winrevair is on pace to clear $2 billion in its second full year post-launch, and Animal Health grew 8% in the quarter with both livestock and companion-animal categories contributing. The strongest counterargument is that each of those growth engines runs into a patent cliff or a regulatory headwind within the next three years. The forward variables to track over the next twelve weeks are the Terns MK-4208 launch readiness in chronic myeloid leukemia, the October PDUFA date for ifinatamab deruxtecan in small-cell lung cancer, the September PDUFA date for the Winrevair HYPERION label update, and any new material event filing announcing the next major business development transaction.